Related Experiment Video
Updated: Dec 30, 2025
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.1K
[Therapeutic innovations for hemophilia]
Cedric Hermans1, Catherine Lambert1
1Unité d'hémostase-thrombose, Service d'hématologie, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Bruxelles.
Revue Medicale Suisse
|January 22, 2020
Summary
New hemophilia treatments offer improved options beyond frequent intravenous factor infusions. These advancements include longer-acting factors, novel antibodies, and promising gene therapies for patients.
Area of Science:
- Hematology
- Biotechnology
- Pharmacology
Background:
- Current hemophilia treatment involves frequent intravenous factor VIII (FVIII) or IX (FIX) concentrate infusions.
- This regimen is burdensome, costly, and carries a risk of inhibitor development.
- Existing treatments are derived from plasma or produced via biotechnology.
Purpose of the Study:
- To review novel and emerging treatment strategies for hemophilia.
- To highlight advancements offering improved patient outcomes and convenience.
Main Methods:
- Review of recent clinical studies and therapeutic developments in hemophilia management.
- Analysis of new formulations, biologics, and gene therapy approaches.
Main Results:
- Development of FVIII and FIX concentrates with extended half-lives.
- Emergence of a bispecific monoclonal antibody mimicking FVIII activity.
- Evaluation of subcutaneous administration strategies and promising gene therapy trials.
Conclusions:
- Novel treatments offer significant improvements over traditional hemophilia care.
- These advancements provide new therapeutic perspectives, potentially reducing treatment burden and improving quality of life for hemophilia patients.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
01:29Venous Thrombosis III: Interprofessional Care
234
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
234
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
990
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
990
01:29Microorganisms in Medicine and Therapeutics
870
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
870
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
393
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
393